Moclobemide Sandoz

Moclobemide, the active ingredient in Moclobemide Sandoz, is a reversible monoamine oxidase inhibitor presented as a tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients, helping to improve mood and functional capacity.

GNH USA supplies Moclobemide Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved documentation for each batch, ensuring reliable access across diverse markets. Customers benefit from dedicated technical support and flexible shipping options tailored to local requirements.

Moclobemide is an antidepressant that acts by reversible inhibition of monoamine oxidase A, primarily used in mood disorders. - Major depressive disorder: alleviates depressive symptoms and improves overall mood in adult patients.

Common Side Effects: - Nausea - Headache - Dizziness - Insomnia

Serious or Rare Side Effects: - Hypertensive crisis when combined with tyramine‑rich foods - Serotonin syndrome with other serotonergic agents - Severe liver injury or hepatitis

Before starting therapy, evaluate cardiovascular status and blood pressure. Avoid tyramine‑rich foods to prevent hypertensive episodes. Monitor for signs of serotonin syndrome, especially when combined with other serotonergic drugs. Review all concomitant medications for potential MAOI interactions. Pregnancy and lactation: use only if the expected benefit outweighs potential risk. Store at ambient temperature: keep in the original container, protect from moisture and light.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs): risk of serotonin syndrome. - Serotonin‑norepinephrine reuptake inhibitors (SNRIs): additive serotonergic effect. - Meperidine and other opioids: may precipitate hypertensive crisis.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: possible enhanced hypotensive effect. - Cimetidine: may increase moclobemide plasma concentrations.